Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN-gamma-secreting HAdV antigen specific T cells
- Development stage
- Phase 1
- Lead developer
- Mari Dallas
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
IFN-gamma-secreting HAdV antigen specific T cells is an investigational adoptive cellular immunotherapy being developed by Mari Dallas for the treatment of refractory human adenovirus (HAdV) infections in patients following allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the selection of donor-derived T cells that specifically recognize HAdV antigens and secrete interferon-gamma (IFN-γ) upon activation. These selected cells are isolated from a compatible donor using the CliniMACS Prodigy System and infused into the recipient to restore virus-specific cellular immunity. This approach aims to provide a targeted immune response to clear the viral infection in immunocompromised patients who have failed standard antiviral treatments.
- Other names
- Adenovirus-specific T cellsHAdV-specific T cellsAdoptive T cell therapy for adenovirusIFN-gamma-secreting human adenovirus antigen specific T cells
02
Targets
Human adenovirus species F type 40/41 hexon-derived peptide–HLA class I complex
Beyond the preview
Go deeper on IFN-gamma-secreting HAdV antigen specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN-gamma-secreting HAdV antigen specific T cells.